- Home
- NCSM vs IGMS Comparison
NCSM vs IGMS Comparison
Compare NCSM & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NCSM
- IGMS
- Stock Information
- Founded
- NCSM 2006
- IGMS 1993
- Country
- NCSM United States
- IGMS United States
- Employees
- NCSM N/A
- IGMS N/A
- Industry
- NCSM Oilfield Services/Equipment
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- NCSM Energy
- IGMS Health Care
- Exchange
- NCSM Nasdaq
- IGMS Nasdaq
- Market Cap
- NCSM 76.3M
- IGMS 82.1M
- IPO Year
- NCSM 2017
- IGMS 2019
- Fundamental
- Price
- NCSM $29.94
- IGMS $1.36
- Analyst Decision
- NCSM
- IGMS Hold
- Analyst Count
- NCSM 0
- IGMS 8
- Target Price
- NCSM N/A
- IGMS $6.00
- AVG Volume (30 Days)
- NCSM 8.1K
- IGMS 1.2M
- Earning Date
- NCSM 07-30-2025
- IGMS 08-13-2025
- Dividend Yield
- NCSM N/A
- IGMS N/A
- EPS Growth
- NCSM N/A
- IGMS N/A
- EPS
- NCSM 3.27
- IGMS N/A
- Revenue
- NCSM $168,704,000.00
- IGMS $2,681,000.00
- Revenue This Year
- NCSM $7.17
- IGMS $134.30
- Revenue Next Year
- NCSM $5.44
- IGMS $22.37
- P/E Ratio
- NCSM $9.17
- IGMS N/A
- Revenue Growth
- NCSM 18.16
- IGMS 27.36
- 52 Week Low
- NCSM $15.90
- IGMS $0.92
- 52 Week High
- NCSM $38.95
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- NCSM 45.45
- IGMS 60.17
- Support Level
- NCSM $29.54
- IGMS $1.12
- Resistance Level
- NCSM $30.82
- IGMS $1.38
- Average True Range (ATR)
- NCSM 1.10
- IGMS 0.06
- MACD
- NCSM -0.10
- IGMS 0.02
- Stochastic Oscillator
- NCSM 23.50
- IGMS 90.32
About NCSM NCS Multistage Holdings Inc.
NCS Multistage Holdings Inc is a provider of engineered products and support services that facilitate the optimization of oil and natural gas well construction, well completions and field development strategies. NCS provides its products and services to exploration and production companies for use in onshore wells, predominantly wells that have been drilled with horizontal laterals in unconventional oil and natural gas formations. The company's offering is its fracturing systems products and services, which enable efficient pinpoint stimulation: the process of individually stimulating each entry point into a formation targeted by an oil or natural gas well. It sell products and services in North America and in selected international markets.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.